The aim is to determine the safety profile and tolerability of PIPAC with oxaliplatin by assessment of dose limiting toxicities and the adverse event profile. The secondary objective is to evaluate the clinical and pathological response of PIPAC with oxaliplatin as well as to identify the pharmacokinetic profile of oxaliplatin administered via PIPAC.